Effect of biphasic insulin aspart 30 combined with metformin on glycaemic control in obese people with type 2 diabetes.
Combination therapy consisting of biphasic insulin aspart 30 bid with metformin provide better glycaemic control in obese patients with diabetes mellitus type 2. In our study, patients who were treated with 2550 mg of metformin, administered in three daily doses had poor glycaemic control. Three months after switching from metformin therapy to treatment with biphasic insulin aspart 30 + metformin twice a day, glycaemic control improved with significant reduction in hemoglobin HbA1c, fasting blood glucose and postprandial blood glucose levels. Biphasic insulin aspart 30 in combination with metformin administered twice a day may be recommended as a starting insulin treatment in obese diabetic persons whose glycaemic control remained poor while on oral metformin therapy alone.
Ascić-Buturović
Belma
B
Endocrinology Clinic, Diabetes and Metabolic Diseases, University of Sarajevo Clinics Centre, Bolnicka 25, 71 000 Sarajevo, Bosnia and Herzegovina.
D000284:Administration, Oral; D000368:Aged; D061265:Biphasic Insulins; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy*; D007328:Insulin / Q000031:analogs & derivatives* / Q000494:pharmacology; D061267:Insulin Aspart; D007336:Insulin, Isophane; D049528:Insulin, Long-Acting; D008297:Male; D008687:Metformin / Q000494:pharmacology*; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D061265:Biphasic Insulins; D007328:Insulin; D049528:Insulin, Long-Acting; C557564:insulin aspart, insulin aspart protamine drug combination 30:70; D007336:Insulin, Isophane; D008687:Metformin; D061267:Insulin Aspart